Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
April 18, 2024

Biocon signs licensing and supply deal for diabetes drug in Brazil

Biocon, an India-based biopharmaceutical company, has entered into an exclusive licensing and supply agreement with Brazilian specialty pharmaceutical company Biomm for the commercialisation of Semaglutide (gOzempic), a drug used to improve glycemic control in adults with type-2 diabetes.

Brazil is claimed to be the fifth country in the world with the highest incidence of diabetes. Credit: Tesa Robbins from Pixabay.